Response to Letter to the Editor: "p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer"

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3518-3519. doi: 10.1210/jc.2018-01094.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Mutation
  • Proto-Oncogene Proteins c-ret / genetics
  • Thyroid Neoplasms*

Substances

  • Proto-Oncogene Proteins c-ret
  • RET protein, human